Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13i vs Prevnar 13 in Healthy Infants
NCT07017777Phase 3Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of iPneucia in pneumococcal infection, sponsored by CanSino Biologics Inc.. Started Nov 2025; status: active, not recruiting.
02
Drugs
iPneucia
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07017777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017777.